Binding and Degradation of Low Density Lipoproteins by Cultured Human Fibroblasts

COMPARISON OF CELLS FROM A NORMAL SUBJECT AND FROM A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA*

(Received for publication, January 14, 1974)

JOSEPH L. GOLDSTEIN† and MICHAEL S. BROWN

From the Divisions of Medical Genetics and Gastroenterology-Liver, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas 75235

SUMMARY

125I-Labeled low density lipoproteins were found to associate with monolayers of cultured normal fibroblasts by two processes—one of high affinity and one of low affinity. The high affinity association appeared to represent binding of the low density lipoprotein to specific receptor sites on the cell surface. This binding process exhibited saturation kinetics at low concentrations of the lipoprotein and competition by related molecules such as very low density lipoproteins. In addition, this process was stimulated by the presence of calcium in the culture medium and could be destroyed by limited treatment of the cells with pronase. The other process, designated low affinity uptake, may represent nonspecific endocytosis since the uptake was proportional to the lipoprotein concentration in the medium with no apparent saturation and because it showed no competition by very low density lipoproteins, no stimulation by calcium, and no destruction by pronase treatment. The 125I-labeled low density lipoproteins associated with normal cells by either the high or low affinity process were degraded by proteolysis to trichloroacetic acid-soluble material, most of which was 125I-tyrosine.

In normal cells, binding of low density lipoproteins to the high affinity membrane receptor sites appears to serve two functions: (a) it results in suppression of the synthesis of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-controlling enzyme in cholesterol biosynthesis, and (b) it facilitates the degradation of low density lipoproteins when they are present in the culture medium at low concentrations (i.e. high affinity degradation). Cultured cells from subjects with the homozygous form of familial hypercholesterolemia, which were found to lack the high affinity binding process, were resistant to suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by low density lipoproteins and were also deficient in high affinity degradation. On the other hand, these mutant cells showed a normal low affinity uptake of low density lipoproteins and were able to degrade these lipoproteins when they were present in the culture medium at high concentrations. The possibility is raised, therefore, that a prerequisite for the regulation of cholesterologenesis in cultured fibroblasts is the initial binding of low density lipoproteins to the high affinity surface receptor sites and that a defect in this process represents the primary genetic abnormality in the disorder familial hypercholesterolemia.

In cultured human fibroblasts, the rate of cholesterol synthesis is controlled by the content of low density lipoproteins in the culture medium (1-4). In recent studies, we have shown that LDL suppresses cholesterol synthesis by inhibiting the synthesis of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-controlling enzyme in the cholesterol biosynthetic pathway (1-4). In order to produce this inhibition, LDL must bind to specific high affinity receptor sites on the cell membrane (5). In cultured fibroblasts from subjects with the homozygous form of familial hypercholesterolemia, this high affinity binding of LDL is deficient (5). As a consequence of this genetic defect, LDL fails to suppress HMG-CoA reductase activity and cholesterol is overproduced (2).

In the course of studying the binding of 125I-LDL to normal fibroblasts, it was noted that the bound material was degraded to a product that was dialyzable and could no longer be precipitated with trichloroacetic acid (5). The present studies were designed to characterize this degradative process in more detail and to examine its relationship to the binding process in normal and hypercholesterolemic cells. The data demonstrate that at

* This research was supported by American Heart Association Grant 72629 and the National Institutes of Health Grants GM 19258 and HL 16024.
† Recipient of a Research Career Development Award GM 70,277-01 from the National Institute of General Medical Sciences.

1 The abbreviations used are: HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LDL, low density lipoproteins; VLDL, very low density lipoproteins; HDL, high density lipoproteins; Tricine, N-tris(hydroxymethyl)methylglycine.

2 For the sake of convenience, the term "hypercholesterolemic
low LDL concentrations high affinity binding is rate-limiting in the process by which cultured fibroblasts degrade this lipoprotein. In the hypercholesterolemic cells, the defect in high affinity binding results in a reduced ability to degrade LDL. This defect may be causally related to the high serum levels of LDL that are characteristic of familial hypercholesterolemia.

**EXPERIMENTAL PROCEDURE**

**Materials**—

| 125| I-LDL (carrier free in 0.05 n NaOH) was obtained from Schwarz-Mann. |
| 125| I-Labeled bovine serum albumin (29 Ci per mmole) was purchased from New England Nuclear Corp. |
| 125| I-Labeled cholesterol and albumin stock solution (Cat. No. 894-10) were purchased from Sigma Chemical Co. |
| 3| Iodo-l-thyroxine was obtained from Aldrich Chemical Co. Total thyrombin (bovine origin) was purchased from Parke, Davis, and Co. |
| H2O2 (30% solution) | was obtained from Matheson. Pronase from Streptomyces griseus, R grade (45,000 units per g) was obtained from Calbiochem. A monospecific goat antisem to human LDL was obtained from Hyland Laboratories. Silica Gel G (without gypsum) and cellulose (polygram ccl 300) coated thin layer chromatography sheets with plastic backings were obtained from Brinkmann Industries. Eagle's minimum essential medium (Cat. No. F-12), penicillin (10,000 units per ml)-streptomycin (10 mg per ml) solution, tryspin-EDTA solution (1X), nonessential amino acids solution (100 X), and Dulbecco's phosphate-buffered saline (0.9% NaCl) were purchased from GIBCO. Potassium phosphate (KH2PO4), Tricine (2-[N-morpholinoo]ethane sulfonic acid), and 0.1% EDTA from healthy subjects who had been fasted for 15 hours. VLDL (d < 1.006 g per ml) was isolated from the blood of a patient with endogenous hypertriglyceridemia associated with familial hypercholesterolemia (2). All cells were cultured in Falcon Plastics. Fetal calf serum was obtained from Hyland Laboratories. Glycerophosphate (8.47 Ci per mole). The [3H]mevalonate formed was isolated by thin layer chromatography and counted with an internal standard of [3H]mevalonolactone to correct for incomplete recovery (13).

**EXPERIMENTAL PROCEDURE**

**Materials**—

| 125| I-LDL was prepared by Dr. David W. Bilheimer of the University of Texas using a modification (9) of the iodine monochloride method of MacFarlane (10). Several preparations were used, all of which were dialyzed extensively into 0.15 M NaCl and 0.3 M EDTA, pH 7.4, and contained less than 1 atom of iodine for each LDL molecule. The final specific activities varied between 600 and 1000 cpm per mg of protein. In all preparations, more than 50% of the radioactivity was precipitated by incubation with 15% trichloroacetic acid at 90°, at least 91% was precipitated by a monospecific goat antisem to human LDL, and less than 2% was extractable into chloroform-methanol (11). When prepared by this method, the [125] I-LDL was able to suppress HMG-CoA reductase activity of normal fibroblasts in a manner similar to that of native LDL (5). The [125] I-LDL was stored at 4° and retained full immunogenic and cell binding activity for at least 1 month. For binding experiments the [125] I-LDL was diluted with native LDL to give the final specific activity indicated in the legend to each figure or table.

**125| I-LDL Binding to Intact Fibroblasts**—

Cells were grown in dishes as described above, and on Day 7 after 24 hours of growth monolayers containing harvested cells were incubated for 2 min at 4° and the precipitate was removed by centrifugation. To a 1-ml aliquot of the supernatant were added 10 μl of 40% (v/v) KI and 40 μl of 30% H2O2. After incubation at room temperature for 5 min, the mixture was extracted with 2 ml of CHCl3 to remove free iodine (see below), after which 0.5 ml of the aqueous fraction was removed and the precipitate was formed per mg of total cell protein. Duplicate determinations of [125] I-LDL binding varied by less than 10% of the mean value.

**HMG-CoA Reductase Assay**—

Cell extracts for measurement of HMG-CoA reductase activity were prepared by a nonionic detergent as previously reported (4). Aliquots (50 to 100 μg of soluble protein) were incubated for 120 min at 37° in a final volume of 0.2 ml containing 0.1 M potassium-phosphate, pH 7.5, 20 μM glucose 6-phosphate, 2.5 mM TPN, 0.1 μM unlabeled substrate dehydrogenase; 4 mM dithiothreitol; and 3 x 10^-6 M [14C]HMG-CoA (8.47 Ci per mole). The [14C]mevalonate formed was isolated by thin layer chromatography and counted with an internal standard of [3H]mevalonolactone to correct for incomplete recovery (13).
RESULTS

When $^{125}$I-LDL was incubated with monolayers of intact fibroblasts, the LDL was degraded to material that was soluble in 10% trichloroacetic acid (Fig. 1). To eliminate contamination by the small amount of free iodide that persisted in the $^{125}$I-LDL preparation despite extensive dialysis, the acid soluble material formed by the cells was oxidized with hydrogen peroxide and then extracted with chloroform. Control experiments showed that under these conditions greater than 95% of free iodide added as $^{125}$I-sodium was extracted into the chloroform phase.

When this extraction procedure was applied to the trichloroacetic acid-soluble material formed by the cells, a constant fraction of the radioactivity (about 65%) remained in the water phase at every point. The formation of this iodide-free, acid-soluble degradative product of LDL, hereafter referred to as acid-soluble material, was absolutely dependent on the presence of cells and was linear with time up to at least 30 hours (Fig. 1A). At this point, 12% of the total radioactivity in the medium had been converted to acid-soluble material.

To determine the relation between the degradative process and the previously described binding of $^{125}$I-LDL to fibroblasts (5), the time courses of binding and degradation were compared (Fig. 1B). Whereas the amount of $^{125}$I bound to the cells reached a maximum at 2 hours and remained constant for the next 28 hours, the rate of formation of acid-soluble material proceeded in a linear fashion over the entire 30-hour period after an initial lag phase. The 2-hour lag phase corresponded to the time required to establish maximal binding (Fig. 1B).

Despite the accumulation of acid-soluble material in the medium, the $^{125}$I bound to the cells remained precipitable by trichloroacetic acid (Table I). About 50% of this bound material was precipitable by a monospecific antibody to LDL after the cells were solubilized in 1% sodium deoxycholate.

To demonstrate directly the conversion of bound $^{125}$I-LDL to acid-soluble material, cells which had been preincubated at $4^\circ$ with $^{125}$I-LDL were transferred to medium without $^{125}$I-LDL and were incubated at either 4 or $37^\circ$ (Fig. 2). At the beginning of the second incubation, all the radioactivity bound to the cells was precipitable with trichloroacetic acid. At $37^\circ$, nearly all of this bound radioactivity was released to the medium within 3 hours and approximately 65% had been converted to acid-soluble material. The remaining 35% of the released material was precipitable both by trichloroacetic acid and by a specific antibody to LDL. In contrast, at $4^\circ$ only about 35% of the $^{125}$I bound to the cells was released and all of this was precipitable by trichloroacetic acid (Fig. 2). Thus, while the release of presumably intact LDL from the cell occurred independent of temperature, the conversion to acid-soluble material was temperature-dependent.

Although the release of $^{125}$I-LDL from the cell at $37^\circ$ was associated with partial degradation of the LDL molecule, the binding sites on the cell did not appear to be altered. Table II demon-

![Fig. 1. Time course of degradation of $^{125}$I-LDL to acid-soluble material by intact fibroblasts and its relation to binding. Cell monolayers were prepared in dishes as described under "Experimental Procedure." At zero time the medium was replaced with 2 ml of Medium A containing 5 pg per ml of $^{125}$I-LDL (200 cpm per ng) and the cells were incubated at 37°. As a control for spontaneous degradation of the $^{125}$I-LDL, dishes without cells were incubated under identical conditions. At each indicated time, the medium from a single dish was removed, its content of acid-soluble material was measured (●, ▲), and the amount of $^{125}$I bound to the cells was determined (▲). The cellular protein content of each dish averaged 0.4 mg (range, 0.37 to 0.42 mg).](http://www.jbc.org/)

<table>
<thead>
<tr>
<th>Time of incubation (hr)</th>
<th>Total $^{125}$I bound to cells (cpm x 10$^{-4}$/dish)</th>
<th>Acid-soluble radioactivity (cpm x 10$^{-4}$/dish)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Medium</td>
<td>Cells</td>
</tr>
<tr>
<td>3</td>
<td>24.7</td>
<td>50.0</td>
</tr>
<tr>
<td>6</td>
<td>21.7</td>
<td>108.0</td>
</tr>
<tr>
<td>24</td>
<td>15.8</td>
<td>347.6</td>
</tr>
</tbody>
</table>

Table I

Distribution of acid-soluble material after incubation of normal fibroblasts with $^{125}$I-LDL

Cell monolayers were prepared in dishes as described under "Experimental Procedure." At the beginning of the experiment, the medium was replaced with 2 ml of Medium A containing 5 pg per ml of $^{125}$I-LDL (200 cpm per ng) and the cells were incubated at 37°. At the indicated time, the medium was removed and its content of acid-soluble material was measured. The cell monolayers were washed 6 times as described under "Experimental Procedure" and the cells from each dish were scraped with a rubber policeman into 2 ml of Medium A. Aliquots of 0.1 ml were removed for determination of total $^{125}$I radioactivity bound to the cells and the remaining 1.9 ml of the cell extract were processed for measurement of its content of acid-soluble material. Each value represents the mean of duplicate dishes.

![Downloaded from](http://www.jbc.org/)
strates that after release of bound LDL from the cell, the receptor site was able to rebind the original amount of $^{125}$I-LDL.

Fig. 3 compares the relation between the concentration of LDL and the extent of binding and the rate of degradation. In normal cells at concentrations of LDL below 25 $\mu$g per ml, the amount of binding rose sharply and linearly with increasing amounts of LDL; this component of the normal binding curve has been designated high affinity binding (Fig. 3A). At levels of LDL above 25 $\mu$g per ml, binding continued to increase but the slope of the line relating binding and LDL concentration was considerably less steep, suggesting that at these higher LDL levels a second process was taking place, designated low affinity binding. In cells from a subject with homozygous familial hypercholesterolemia, binding was linearly related to LDL concentration throughout the entire range. The slope of this line was identical with the second component of the normal binding curve (Fig. 3). These data are consistent with the previous conclusions derived from Scatchard plot analysis of $^{125}$I-LDL binding (5) and suggest that the hypercholesterolemic cells lack the high affinity binding component. Remarkably similar curves were obtained when the rates of LDL degradation in normal and hypercholesterolemic cells were plotted as a function of LDL concentration (Fig. 3B). Thus, whereas normal cells appeared to have both low affinity and high affinity processes for degradation of LDL, the latter was deficient in the hypercholesterolemic cells. To date, we have examined cell lines from 5 unrelated subjects with the homozygous form of familial hypercholesterolemia and all 5 have shown a similar deficiency in high affinity binding and high affinity degradation.

To facilitate a comparison of the high affinity processes for binding and degradation in normal cells, the data were replotted using a "slope peeling" technique to subtract the contribution of the low affinity processes (Fig. 4). Both binding and degradation appeared to reach saturation at about 35 $\mu$g per ml. Double reciprocal plots of these data indicated that the apparent $K_m$ values for high affinity binding and degradation were similar (about 10 $\mu$g per ml) (Fig. 4, inset).

Another method for evaluation of high affinity binding consists of determining the amount of radioactivity bound to the receptor in the absence and presence of an excess of nonradioactive material (14). Subtraction of the latter from the former gives the amount of displaceable or high affinity binding. When this

When the dilution in specific activity of the $^{125}$I-LDL due to the addition of the excess native LDL is taken into account, it can be seen that the absolute amount of radioisotope material bound and degraded by the cells in the presence of native LDL increased rather than decreased. However, since the purpose of these ex-
The experiments were to determine the amount of $^{125}$I-LDL that could be bound to the concentration of LDL in normal fibroblasts. At each LDL concentration the amounts of high affinity binding and high affinity degradation of $^{125}$I-LDL were calculated from the experimental data in Fig. 3 by subtracting from the total binding or degradation the amounts contributed by the low affinity processes. The latter were derived by extrapolation from the slopes of the terminal linear portions of the appropriate concentration curves. For each microgram per ml of LDL, the calculated low affinity binding and low affinity degradation were 366 and 910 cpm per ng of cellular protein, respectively. The inset shows a double reciprocal plot of these high affinity data for binding and degradation. •, high affinity binding; ▲, high affinity degradation.

When this same method was applied to the degradation process, the normal cells again showed a saturation curve that was similar to the binding curve, while the hypercholesterolemic cells showed a markedly diminished amount of high affinity degradation.

Further support for this hypothesis is provided by the data in Fig. 6, which show that the rate of degradation in both normal and hypercholesterolemic cells is directly proportional to the amount of LDL bound. In normal cells the efficiency of degradation appeared to be somewhat greater for LDL bound at the high affinity site as compared to LDL bound at the low affinity site. This is reflected by the break in the normal curve, which represents the point at which the high affinity binding sites become saturated with LDL.

If high affinity binding of LDL is a prerequisite for high affinity degradation, then VLDL, which displaces LDL from its high affinity binding site (5), should also be less effective in inhibiting degradation of LDL by fibroblasts. Further support for this hypothesis is provided by the data in Fig. 6, which show that the rate of degradation in both normal and hypercholesterolemic cells is directly proportional to the amount of LDL bound. In normal cells the efficiency of degradation appeared to be somewhat greater for LDL bound at the high affinity site as compared to that bound at the low affinity site. This is reflected by the break in the normal curve, which represents the point at which the high affinity binding sites become saturated with LDL.

When high affinity binding of LDL is a prerequisite for high affinity degradation, then VLDL, which displaces LDL from its high affinity binding site (5), should also compete for degradation. On the other hand, HDL, which is much less effective in competing for binding (5), should also be less effective in inhibiting degradation. The experimental results described in Fig. 7 are consistent with these predictions. The data also show that the low affinity degradative process was not inhibited by any of the lipoproteins.

High affinity binding and degradation of LDL in normal cells were both strictly dependent on the calcium concentration in the incubation medium (Fig. 8). When $^{125}$I-LDL was incubated with cells in isotonic buffer containing only Tris and NaCl, the addition of increasing amounts of calcium resulted in a 3-fold
rise in binding with half-maximal effect achieved at 0.5 mM (Fig. 8A). In the same experiment, the addition of calcium stimulated degradation 6-fold with a maximal effect achieved at 0.2 mM (Fig. 8B). The data thus suggest that calcium may be acting at two different sites—one required for binding and the other required for degradation. At high levels of LDL, calcium had no effect on either binding or degradation (Fig. 8), suggesting that this ion is not required for the low affinity process. In identical experiments, magnesium at 2 mM was unable to replace calcium.

To determine whether modification of the cell surface could affect high affinity binding and degradation, normal and hypercholesterolemic cells were treated with pronase under conditions that are known to alter cell surface receptors without inhibiting cell growth (15). In normal cells, pronase treatment caused a 66% reduction in high affinity binding and a 55% reduction in the rate of LDL degradation (Table III). Since neither binding nor degradation was significantly reduced in the hypercholesterolemic cells (Table III), the data suggest that pronase was acting mainly on high affinity sites. This hypothesis was confirmed by the experiment shown in Fig. 9, in which pronase treatment of normal cells caused a reduction only in high affinity binding and had no effect on the slope of the low affinity process.

If, as suggested by our previous data, suppression of HMG-CoA reductase activity is mediated by binding of LDL to the high affinity sites (5), destruction of these sites with pronase should reduce the ability of normal cells to respond to LDL. Fig. 10 shows that after pronase treatment the normal cells did become resistant to LDL-mediated suppression of HMG-CoA reductase activity. On the other hand, the hypercholesterolemic cells, which lack the high affinity binding site and thus are genetically resistant to LDL-mediated suppression (5), showed no change in their LDL responsiveness.

An additional observation in these studies was that pronase itself reduced the HMG-CoA reductase activity of both the normal and the hypercholesterolemic cells. Since insulin is known to stimulate HMG-CoA reductase activity in both normal and hypercholesterolemic fibroblasts (4) and since the insulin receptor is

<table>
<thead>
<tr>
<th>Cell type</th>
<th>125I bound to cells</th>
<th>Acid-soluble material in medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal .</td>
<td>51</td>
<td>2 pm x 10^6/mg protein</td>
</tr>
<tr>
<td>Homozygote</td>
<td>Subject A .</td>
<td>9.5</td>
</tr>
<tr>
<td></td>
<td>Subject B .</td>
<td>11.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>122</td>
</tr>
</tbody>
</table>

The extent of high affinity binding and the rate of degradation of 125I-LDL in normal fibroblasts were both significantly higher in actively dividing cells as compared with cells in the stationary phase of growth (Table IV). This finding correlates with the previous observation that when LDL is removed from the medium the relative rise in HMG-CoA reductase activity is greater in growing cells than in confluent cells (4). It was also observed that the extent of binding and the rate of degradation of 125I-LDL were both about 2-fold greater in cells studied after the 14th day and were both about 2-fold greater in cells studied after the 14th day.

The extent of binding and degradation of 125I-LDL in normal fibroblasts was significantly higher in actively dividing cells as compared with cells in the stationary phase of growth (Table IV). This finding correlates with the previous observation that when LDL is removed from the medium the relative rise in HMG-CoA reductase activity is greater in growing cells than in confluent cells (4). It was also observed that the extent of binding and the rate of degradation of 125I-LDL were both about 2-fold greater in cells studied after the 14th day.

During the experiment, the medium was replaced with 2 ml of Medium A from which the lipoprotein-deficient serum was omitted (9). After incubation at 37°C for 45 min without shaking, the medium was removed, the monolayers were washed once with 2 ml of Dulbecco’s phosphate-buffered saline, and 2 ml of fresh Medium A containing 10 μg per ml of 125I-LDL (160 cpm per ng) were added. After incubation at 37°C for 6 hours, the medium was removed, its content of acid-soluble material was measured, and the amount of 125I bound to cells was determined. Each value represents the mean of duplicate determinations. Subject A and Subject B are two different homozygotes with familial hypercholesterolemia.

*An additional observation in these studies was that pronase itself reduced the HMG-CoA reductase activity of both the normal and the hypercholesterolemic cells. Since insulin is known to stimulate HMG-CoA reductase activity in both normal and hypercholesterolemic fibroblasts (4) and since the insulin receptor is
transfer as compared with those studied after the 36th transfer (data not shown).

To characterize the low affinity uptake of LDL in more detail and to determine whether it could be attributed to endocytosis of macromolecules as is seen with albumin (17), uptake of \(^{125}\)I-LDL and \(^{131}\)I-albumin were compared. If both proteins were taken up by the nonspecific endocytosis of droplets of medium, then the volume of medium cleared by the uptake process should be the same for both proteins and should be independent of the protein concentration. Table V demonstrates that at high protein concentrations the clearance volume was similar for both albumin and LDL in the normal and hypercholesterolemic cells. At low protein concentrations, the clearance volumes for albumin in the normal cells and LDL in the hypercholesterolemic cells remained equal to each other and unchanged from their respective values at the high protein concentrations. These data suggest that the low affinity uptake process observed in the normal cells at high LDL levels and in the hypercholesterolemic cells at all LDL levels was due to endocytosis. The data in Table V also demonstrate that at low LDL concentrations in the normal cells, the clearance volume was about 10-fold greater than that which could be attributed to endocytosis, confirming that this high affinity uptake process was the result of a different mechanism.

To study further the acid-soluble material formed as a result of the high affinity degradation of \(^{125}\)I-LDL by normal fibroblasts, the acid-soluble material produced after incubation of the cells with \(^{125}\)I-LDL at 5 \(\mu\)g per ml was fractionated by Sephadex G-10 chromatography (Fig. 11). Nearly all of the acid-soluble material formed under these conditions was found in the inclusion volume of the column, confirming the earlier observation that most of the acid-soluble material was of a small enough molecular size to be dialyzable (5). Five discrete peaks were identified (Fig. 11C). The formation of the two major peaks (II and V) was dependent on the presence of cells and was approximately linear with time. On the other hand, the three minor peaks (I, III, and IV) were present in the \(^{125}\)I-LDL preparation incubated without cells (Fig. 11A).

Peak V, which represented over 60% of the acid-soluble material, was eluted from the G-10 Sephadex column near the salt peak (Fig. 11C). Thin layer chromatography of this material in two different solvent systems showed that it had the same \(R_P\) value as 3-iodo-1-tyrosine (Fig. 12). Similar results were also obtained after ascending paper chromatography in collidine-NH\(_2\)OH-water. Although a precise characterization of Peaks I to IV has not been made, they would appear to represent small...
Fig. 11 (left). Sephadex G-10 chromatography of the 125I-labeled acid-soluble material formed by the normal cells. Cell monolayers were prepared in dishes as described under "Experimental Procedure." At the beginning of the experiment, the medium in each dish was replaced with 2 ml of Medium A containing 5 μg per ml of 125I-LDL (600 cpm per ng). One group of 10 dishes was incubated for 1 hour at 37° (B) and another group of 10 dishes was incubated for 6 hours at 37° (C). A control group of 10 dishes containing no cells was incubated for 6 hours at 37° under identical conditions (A). After incubations, the medium from each group of 10 dishes was pooled, lyophilized, and resuspended in 1.5 ml of distilled water. Each solution (containing approximately 49 X 10⁶ cpm of 125I) was then adjusted to 10% (w/v) trichloroacetic acid, incubated at 4° overnight, and the precipitate was removed by centrifugation. To each supernatant (2 ml) were added 20 μl of 40% KI (w/v) and 80 μl of 30% H₂O₂. After incubation at 24° for 5 min, each mixture was extracted with 4 ml of CHCl₃, after which the acid-soluble phase (1.5 ml) was removed for chromatography. The acid-soluble material (750 μl) from A (containing 15,749 cpm), B (containing 49,798 cpm), and C (containing 389,989 cpm) were applied sequentially to a Sephadex G-10 column (28 X 1 cm) equilibrated with 50 mM Tris-Cl, pH 7.5. The column was eluted with the same buffer at a flow rate of 10 ml per hour, and 0.7-ml fractions were collected and counted for radioactivity. The void volume of the column was determined using dextran blue.

Fig. 12 (center). Thin layer chromatography of Fraction V from Sephadex G-10 column. 125I-labeled acid-soluble material was isolated from the medium of normal cells and chromatographed on dextran blue sheets formed during the course of degradation of LDL to its constituent amino acids.

When the acid-soluble material formed by the hypercholesterolemic cells was fractionated on the same G-10 Sephadex column, 5 peaks were also observed (Fig. 13). Although the elution volume of each of these peaks could be correlated with the 5 peaks from the normal cells, the relative distribution of the radioactivity among the peaks was somewhat different. This may reflect a subtle difference in the products formed by the high affinity degradative process of the normal cells and the low affinity process of the hypercholesterolemic cells.

DISCUSSION

The studies presented in this paper demonstrate that the cultured human fibroblasts from normal subjects are able to bind and degrade LDL. LDL can be bound to the cell by two processes—one of high affinity and one of low affinity. That the high affinity process involves binding of LDL to specific receptor...
sites on the cell surface is suggested by the following observations. First, the high affinity binding of LDL is saturable, shows competition with related molecules (such as VLDL), and the amount bound reaches a plateau with time. Second, although its extent is greater at 37°C, high affinity LDL binding can also be demonstrated at 4°C (5). Third, immunologically intact LDL can be dissociated from the cell at 4°C. Fourth, treatments that act largely on the surface of the cell, such as limited pronase digestion (15) and addition of calcium to the medium, profoundly affect the high affinity process.

In contrast to the high affinity binding process that is observed at the low LDL levels, a different type of association predominates when LDL is present in the medium at levels above 25 μg per ml. This low affinity process is characterized by an apparent lack of saturability and competition and a resistance to treatment with either pronase or calcium. In addition, this low affinity process appears to be normal in the hypercholesterolemic cells despite the absence of high affinity receptor sites. Because this low affinity process lacks many of the above mentioned characteristics of surface binding, we believe that it may represent a nonspecific endocytosis of the LDL in solution in the culture medium (17).

Both the high and low affinity uptake processes for LDL appear to provide substrate for the proteolytic enzymes that degrade this lipoprotein. Evidence that high affinity binding is obligatory for high affinity degradation is provided by the following experiments. First, the LDL concentration curves for the extent of high affinity binding and the rate of high affinity degradation are identical. Second, VLDL, which competes with LDL for high affinity binding (5), also competes for high affinity degradation, whereas HDL, which does not effectively compete for high affinity binding (5), does not effectively compete for high affinity degradation. Third, both high affinity binding and degradation are stimulated by the presence of calcium in the medium, while neither process is affected by magnesium. Fourth, treatment of cells with pronase abolishes both high affinity binding and high affinity degradation. Fifth, in cells from subjects with homozygous familial hypercholesterolemia, the absence of high affinity binding is associated with an absence of high affinity degradation. Finally, in experiments soon to be published we have observed that in cells from 6 obligate heterozygotes with familial hypercholesterolemia (i.e., the parents of homozygotes), both the extent of high affinity binding and the maximal rate of high affinity degradation of LDL are reduced to values intermediate between those of 13 normal controls and 5 homozygotes (18).

Uptake of LDL by the low affinity process also results in degradation of the lipoprotein as indicated by (a) the experiments showing identical substrate concentration curves for binding and degradation at high levels of LDL and (b) the observation that the hypercholesterolemic cells have normal low affinity processes for both binding and degradation.

The degradative process in cultured cells appears to be similar regardless of whether LDL is bound to specific high affinity surface membrane receptors or whether it is nonspecifically taken up by the low affinity process. One hypothesis to account for these findings is that when LDL is associated with the cell by either process it becomes incorporated into endocytotic vesicles, where the proteolysis occurs. The LDL bound at high affinity surface receptor sites would be incorporated into such vesicles if the wall of the vesicle were formed by invagination of the portion of the plasma membrane containing the bound LDL. Low affinity incorporation of LDL into the same vesicle would result from nonspecific trapping of the lipoprotein contained in the medium that forms its interior. Once formed, the vesicles containing LDL incorporated by both mechanisms would then fuse with lysosomes containing proteolytic enzymes. Since it is generally believed that macromolecules ingested by endocytosis are degraded by such lysosomal enzymes (19), this mechanism would explain the nearly complete proteolytic degradation of LDL bound by either the high affinity or the low affinity processes in normal cells. Moreover, it would account for the observation that the hypercholesterolemic cells, which lack high affinity binding, can nevertheless degrade LDL by the low affinity process. Also consistent with this interpretation is the finding that the products of the low affinity degradation in the hypercholesterolemic cells appear to be qualitatively the same as those formed by the high affinity process in the normal cells.

Binding of LDL to the high affinity site, in addition to its role in facilitating LDL degradation, is also necessary for suppression of HMG-CoA reductase activity in normal cultured fibroblasts (5). Hence, collective destruction of the high affinity binding site by pronase reduces the ability of normal cells both to degrade LDL and to suppress HMG-CoA reductase activity when LDL is added to the medium, thus producing a phenotype similar to that of the hypercholesterolemic cells. The simplest hypothesis to explain the mechanism by which high affinity binding of LDL leads to suppression of HMG-CoA reductase is that the resultant degradation of LDL releases cholesterol and that cholesterol in turn suppresses enzyme activity. Indeed, previous data have shown that cholesterol administered to cells in a nonlipoprotein form is able to suppress enzyme activity in both the normal and hypercholesterolemic cells (4). However, this hypothesis is not sufficient to account for all the data since incubation of hypercholesterolemic cells with high concentrations of LDL leads to degradation of large amounts of lipoprotein by the low affinity process, yet HMG-CoA reductase activity is not suppressed. Thus, elucidation of the mechanism by which the LDL receptor regulates HMG-CoA reductase activity requires further study.

In summary, from the data presented in this and earlier papers (2-5), we believe that the primary genetic abnormality in familial hypercholesterolemia resides in a gene whose product is necessary for the production of a high affinity cell surface receptor for LDL. A defect in this LDL receptor results in deficient high affinity binding of LDL, and this appears to have at least two important consequences: (a) the cell cannot normally suppress HMG-CoA reductase activity in the presence of LDL and hence it overproduces cholesterol, and (b) the cell cannot degrade LDL when it is present extracellularly in low concentrations. Assuming that the familial hypercholesterolemia gene is expressed in vivo as it is in vitro, both of these secondary abnormalities may be important in producing and maintaining the high levels of serum LDL that are found in patients with this disorder (20).

Acknowledgments—We thank Suzanna E. Dana for her help with the design and performance of many of the experiments. Helen Bohnfalk, Gloria Brunschede, and Jean Helgeson provided excellent technical assistance. We are also grateful to Dr. Edwin L. Bierman for suggesting the method for removing free 125I from 125I-LDL preparations.

REFERENCES
Binding and Degradation of Low Density Lipoproteins by Cultured Human Fibroblasts: COMPARISON OF CELLS FROM A NORMAL SUBJECT AND FROM A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Joseph L. Goldstein and Michael S. Brown


Access the most updated version of this article at http://www.jbc.org/content/249/16/5153

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/249/16/5153.full.html#ref-list-1